<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267279</url>
  </required_header>
  <id_info>
    <org_study_id>SJRC-Reclast</org_study_id>
    <nct_id>NCT01267279</nct_id>
  </id_info>
  <brief_title>Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty</brief_title>
  <official_title>Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spokane Joint Replacement Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spokane Joint Replacement Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized, double-blind trial, BMD of the operated proximal femur after total hip
      replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two
      years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n =
      24) at two weeks and one year after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Study drug group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Zoledronic acid per protocol</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Study drug group</arm_group_label>
    <other_name>Reclast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing primary elective total hip replacement

        Exclusion Criteria:

          -  Osteoporosis (BMD â‰¤-2.5)

          -  Trauma to the operated femur, hip revisions, femoral dysplasia, trochanteric
             osteotomy, inflammatory arthritis

          -  Severe renal impairment

          -  Use of any medications affecting BMD

          -  Known sensitivity to bisphosphonates

          -  Severe dental problems, and pregnancy or being able to conceive and not using reliable
             birth control methods
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Spokane Joint Replacement Center</investigator_affiliation>
    <investigator_full_name>David F. Scott, MD</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

